Affinity Asset Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Affinity Asset Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-562,631	Closed	-$29.7M	–	127
2026 Q1	$29.7M	Buy	562,631 +12,631	+2%	+$519K	1.53%	18
2025 Q4	$22.2M	Buy	+550,000	New	+$12.7M	1.27%	25
2024 Q4	–	Sell	-600,000	Closed	-$5M	–	100
2024 Q3	$5M	Buy	+600,000	New	+$4.94M	0.68%	43
2024 Q2	–	Sell	-450,000	Closed	-$2.95M	–	120
2024 Q1	$2.95M	Buy	450,000 +384,000	+582%	+$2.51M	0.37%	66
2023 Q4	$428K	Sell	66,000 -259,000	-80%	-$1.37M	0.08%	76
2023 Q3	$1.63M	Buy	+325,000	New	+$2.06M	0.46%	49
2022 Q3	–	Sell	-401,268	Closed	-$995K	–	80
2022 Q2	$995K	Buy	+401,268	New	+$801K	0.42%	41

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Affinity Asset Advisors's TERN Position: Q2 2026 in Review

Affinity Asset Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 562,631 shares — an estimated $29.7M sold.

Affinity Asset Advisors first reported a position in TERN in Q2 2022 and held it in 7 quarters. The position peaked at $29.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Affinity Asset Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Affinity Asset Advisors sold 562,631 Terns Pharmaceuticals shares in Q2 2026, an estimated $29.7M.
Affinity Asset Advisors first reported a position in Terns Pharmaceuticals in Q2 2022 and held it in 7 quarters.
Affinity Asset Advisors's Terns Pharmaceuticals position peaked at $29.7M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.